KDM1A and cancer: Given its potential involvement in carcinogenesis, targeting KDM1A is becoming an emerging option for the treatment of cancer (Li et al., 2021), and numerous KDM1A inhibitors are currently undergoing clinical assessment for the treatment of both solid and hematopoietic malignancies (Y. Fang et al., 2019; Karakaidos et al., 2019).